首页> 外文OA文献 >Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

【2h】

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

机译：在阿扎胞苷同情患者命名的患者计划中，首个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合征（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓细胞性白血病（AML）患者反应的有希望的预测指标

页面导航

著录项
相似文献
相关主题

著录项

作者
van der Helm Lieke H.; Alhan Canan; Wijermans Pierre W.; Kooy Marinus van Marwijk; Schaafsma Ron; Biemond Bart J.; Beeker Aart; Hoogendoorn Mels; van Rees Bastiaan P.; de Weerdt Okke; Wegman Jurgen; Libourel Ward J.; Luykx-de Bakker Sylvia A.; Minnema Monique C.; Brouwer Rolf E.; Boer Fransien Croon-de; Eefting Matthijs; Jie Kon-Siong G.; de Loosdrecht Arjan A. van; Koedam Jan; Veeger Nic J. G. M.; Vellenga Edo; Huls Gerwin;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. [J] . van der Helm LH, Alhan C, Wijermans PW, British Journal of Haematology . 2011,第5期

机译：在阿扎胞苷同情患者计划中，第一个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合症（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓性白血病（AML）患者反应的有希望的预测指标。
2. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme [J] . Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans, British Journal of Haematology . 2011,第5期

机译：在阿扎胞苷同情患者命名的患者计划中，首个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合征（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓细胞性白血病（AML）患者反应的有希望的预测指标
3. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. [J] . Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, British Journal of Haematology . 2014,第1期

机译：在阿扎胞苷治疗的第一个周期后，血小板计数增加一倍可预示骨髓增生异常综合症和成寡细胞急性髓细胞性白血病患者的最终反应和生存率，但不会增加修订版IPSS的预后效用。
4. Design of optimal disease and patient-specific chemotherapy protocols for the treatment of Acute Myeloid Leukaemia (AML) [C] . E. Pefani, N. Panoskaltsis, A. Mantalaris International Symposium on Process Systems Engineering . 2012

机译：用于治疗急性髓性白血病（AML）的最佳疾病和患者特异性化疗方案的设计
5. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia but does not add to prognostic utility of the revised IPSS [O] . Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, -1

机译：在阿扎胞苷治疗的第一个周期后血小板计数增加一倍可预测骨髓增生异常综合症和寡粒细胞急性髓细胞性白血病患者的最终反应和生存率但不会增加修订版IPSS的预后效用
6. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme [O] . van der Helm Lieke H., Alhan Canan, Wijermans Pierre W., 2011

机译：在阿扎胞苷同情患者命名的患者计划中，首个阿扎胞苷周期后的血小板加倍是骨髓增生异常综合征（MDS），慢性粒细胞单核细胞白血病（CMML）和急性髓细胞性白血病（AML）患者反应的有希望的预测指标

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

著录项

相似文献

相关主题

期刊订阅